Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.88 EUR | +4.73% | +0.70% | -21.31% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The group shows a rather high level of debt in proportion to its EBITDA.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Environmental Services & Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.31% | 67.17M | - | ||
-29.08% | 213M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BNN Stock
- Ratings BRAIN Biotech AG